BG107384A - ИЗПОЛЗВАНЕ НА PPARгама АГОНИСТ ЗА ПОЛУЧАВАНЕ НА МЕДИКАМЕНТ ЗА ЛЕЧЕНИЕ И ПРОФИЛАКТИКА НА СЪСТОЯНИЯ СВЪРЗАНИ СЪС СЪРДЕЧНА ИНСУЛИНОВА РЕЗИСТЕНТНОСТ - Google Patents

ИЗПОЛЗВАНЕ НА PPARгама АГОНИСТ ЗА ПОЛУЧАВАНЕ НА МЕДИКАМЕНТ ЗА ЛЕЧЕНИЕ И ПРОФИЛАКТИКА НА СЪСТОЯНИЯ СВЪРЗАНИ СЪС СЪРДЕЧНА ИНСУЛИНОВА РЕЗИСТЕНТНОСТ Download PDF

Info

Publication number
BG107384A
BG107384A BG107384A BG10738402A BG107384A BG 107384 A BG107384 A BG 107384A BG 107384 A BG107384 A BG 107384A BG 10738402 A BG10738402 A BG 10738402A BG 107384 A BG107384 A BG 107384A
Authority
BG
Bulgaria
Prior art keywords
insulin resistance
treatment
congestive heart
cardiac
compound
Prior art date
Application number
BG107384A
Other languages
Bulgarian (bg)
English (en)
Inventor
Ameet Nathwani
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG107384A publication Critical patent/BG107384A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG107384A 2000-06-16 2002-12-12 ИЗПОЛЗВАНЕ НА PPARгама АГОНИСТ ЗА ПОЛУЧАВАНЕ НА МЕДИКАМЕНТ ЗА ЛЕЧЕНИЕ И ПРОФИЛАКТИКА НА СЪСТОЯНИЯ СВЪРЗАНИ СЪС СЪРДЕЧНА ИНСУЛИНОВА РЕЗИСТЕНТНОСТ BG107384A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/002347 WO2001095906A1 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions

Publications (1)

Publication Number Publication Date
BG107384A true BG107384A (bg) 2003-09-30

Family

ID=9884792

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107384A BG107384A (bg) 2000-06-16 2002-12-12 ИЗПОЛЗВАНЕ НА PPARгама АГОНИСТ ЗА ПОЛУЧАВАНЕ НА МЕДИКАМЕНТ ЗА ЛЕЧЕНИЕ И ПРОФИЛАКТИКА НА СЪСТОЯНИЯ СВЪРЗАНИ СЪС СЪРДЕЧНА ИНСУЛИНОВА РЕЗИСТЕНТНОСТ

Country Status (15)

Country Link
EP (1) EP1292301A1 (hu)
JP (1) JP2004503499A (hu)
CN (1) CN1592620A (hu)
AP (1) AP2002002688A0 (hu)
BG (1) BG107384A (hu)
BR (1) BR0017254A (hu)
CA (1) CA2436116A1 (hu)
DZ (1) DZ3389A1 (hu)
EA (1) EA200300028A1 (hu)
HU (1) HUP0301103A2 (hu)
IL (1) IL153452A0 (hu)
MX (1) MXPA02012619A (hu)
NO (1) NO20026000L (hu)
WO (1) WO2001095906A1 (hu)
YU (1) YU1203A (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
EP0930882A2 (en) * 1996-08-02 1999-07-28 Institut Pasteur De Lille Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation

Also Published As

Publication number Publication date
BR0017254A (pt) 2004-01-06
NO20026000L (no) 2003-02-11
MXPA02012619A (es) 2003-04-10
NO20026000D0 (no) 2002-12-13
EA200300028A1 (ru) 2003-04-24
HUP0301103A2 (hu) 2003-08-28
EP1292301A1 (en) 2003-03-19
DZ3389A1 (fr) 2001-12-20
AP2002002688A0 (en) 2002-12-31
IL153452A0 (en) 2003-07-06
JP2004503499A (ja) 2004-02-05
YU1203A (sh) 2006-05-25
WO2001095906A1 (en) 2001-12-20
CA2436116A1 (en) 2001-12-20
CN1592620A (zh) 2005-03-09

Similar Documents

Publication Publication Date Title
KR100666591B1 (ko) 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
EP0695183B1 (en) Use of thiazolidinediones for the treatment of atherosclerosis and eating disorders
JP2008260777A (ja) 新規治療
CA2370127A1 (en) Novel method of treatment
AU700826B2 (en) Use of insulin sensitisers for treating renal diseases
JP2000273043A (ja) ピオグリタゾンを含有する耐糖能不全治療剤
JP2000514807A (ja) レプチン耐性の新規な治療
WO2000076488A2 (en) Use of a ppar agonist for treating type 1 diabetes
BG107384A (bg) ИЗПОЛЗВАНЕ НА PPARгама АГОНИСТ ЗА ПОЛУЧАВАНЕ НА МЕДИКАМЕНТ ЗА ЛЕЧЕНИЕ И ПРОФИЛАКТИКА НА СЪСТОЯНИЯ СВЪРЗАНИ СЪС СЪРДЕЧНА ИНСУЛИНОВА РЕЗИСТЕНТНОСТ
JP2001523271A (ja) チアゾリジンジオンおよびアルファ−グルコシダーゼ阻害剤を用いる糖尿病の治療
US20020156106A1 (en) Use of insulin sensitisers for treating renal diseases
ZA200300283B (en) Treatment and prevention of cardiac insulin resistance associated conditions.
AU2000254153A1 (en) Treatment and prevention of cardiac insulin resistance associated conditions
CZ20024067A3 (cs) Léčivo pro léčení nebo profylaxi srdeční rezistence na insulin
OA12831A (en) Treatment and prevention of cardiac insulin resistance associated conditions.
KR20030019434A (ko) 심장 인슐린 내성 관련 증상의 치료 및 예방
US20040266833A1 (en) Novel use of certain insulin sensitizers or ppar-gamma agonists
US20020115699A1 (en) Method for treating renal disease
KR19990036290A (ko) 비인슐린 의존성 진성 당뇨병 환자에 대한 외인성 인슐린 투여량의 감소 방법
CZ2001250A3 (cs) Léčivo pro sníľení postischemického poąkození srdce a/nebo zlepąení funkční obnovy srdce a farmaceutický prostředek s obsahem vychytávače glukózy
CZ7799A3 (cs) Farmaceutický prostředek proti leptinové rezistenci
SK5322000A3 (en) Use of thiazolidinediones for the treatment of hyperglycaemia
NZ506200A (en) Use of a leptine sensitiser in combination with leptin to treat leptine resistance conditions (e.g. obesity)
CZ9904580A3 (cs) Léčivo pro léčbu diabetes mellitus a stavů spojených s diabetes mellitus
AU2005200702A1 (en) Novel method of treatment